Latest Updates on Sarcopenia and Cachexia: Insights from the 17th Sarcopenia, Cachexia, and Wasting Disorders Conference.

Q2 Medicine
Journal of Bone Metabolism Pub Date : 2025-08-01 Epub Date: 2025-08-31 DOI:10.11005/jbm.25.867
Hyunwoo Park, Hyeon Su Kim, Bon-Sang Gu, Hyunbin Kim, Jun-Il Yoo
{"title":"Latest Updates on Sarcopenia and Cachexia: Insights from the 17th Sarcopenia, Cachexia, and Wasting Disorders Conference.","authors":"Hyunwoo Park, Hyeon Su Kim, Bon-Sang Gu, Hyunbin Kim, Jun-Il Yoo","doi":"10.11005/jbm.25.867","DOIUrl":null,"url":null,"abstract":"<p><p>The 17th Sarcopenia, Cachexia, and Wasting Disorders Conference, held from December 6 to 8, 2024, in Washington, DC, showcased groundbreaking advancements in understanding and managing muscle wasting conditions. Drawing on the lecture notes and presentations of internationally recognized experts who spoke at the meeting, this review highlights key insights and recent developments discussed during the conference. This review focuses on sarcopenia, cancer cachexia, and other wasting disorders linked to chronic diseases. Key discoveries included the identification of the Macroautophagy and YouTH Optimizer pathway in muscle regulation, the role of ectodysplasin A2 receptor-nuclear factor-κB-inducing kinase signaling in muscle atrophy, and the impact of mitochondrial dysfunction on systemic health. Advancements in diagnostic tools, including artificial intelligence-powered imaging and novel biomarkers, are transforming the detection and management of these conditions. Emerging therapeutic strategies, such as glucagon-like peptide 2-based treatments, selective androgen receptor modulators, and cytokine inhibitors, are reshaping the therapeutic landscape. The conference underscored the importance of precision medicine, integrating molecular insights with personalized care approaches, and emphasized multidisciplinary rehabilitation to optimize patient outcomes. The conference also highlighted promising clinical advancements, including the HIPGEN trial on placental-expanded stromal cells for muscle regeneration in hip fracture patients and the ponsegromab study targeting growth/differentiation factor-15 inhibition to mitigate cancer cachexia-associated muscle wasting. This review highlights the integration of basic science, innovative diagnostics, and clinical applications as a promising framework for addressing the complex challenges posed by muscle-wasting disorders. As the field progresses, these insights offer hope for improving the quality of life and survival of affected patients.</p>","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 3","pages":"167-179"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444086/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11005/jbm.25.867","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The 17th Sarcopenia, Cachexia, and Wasting Disorders Conference, held from December 6 to 8, 2024, in Washington, DC, showcased groundbreaking advancements in understanding and managing muscle wasting conditions. Drawing on the lecture notes and presentations of internationally recognized experts who spoke at the meeting, this review highlights key insights and recent developments discussed during the conference. This review focuses on sarcopenia, cancer cachexia, and other wasting disorders linked to chronic diseases. Key discoveries included the identification of the Macroautophagy and YouTH Optimizer pathway in muscle regulation, the role of ectodysplasin A2 receptor-nuclear factor-κB-inducing kinase signaling in muscle atrophy, and the impact of mitochondrial dysfunction on systemic health. Advancements in diagnostic tools, including artificial intelligence-powered imaging and novel biomarkers, are transforming the detection and management of these conditions. Emerging therapeutic strategies, such as glucagon-like peptide 2-based treatments, selective androgen receptor modulators, and cytokine inhibitors, are reshaping the therapeutic landscape. The conference underscored the importance of precision medicine, integrating molecular insights with personalized care approaches, and emphasized multidisciplinary rehabilitation to optimize patient outcomes. The conference also highlighted promising clinical advancements, including the HIPGEN trial on placental-expanded stromal cells for muscle regeneration in hip fracture patients and the ponsegromab study targeting growth/differentiation factor-15 inhibition to mitigate cancer cachexia-associated muscle wasting. This review highlights the integration of basic science, innovative diagnostics, and clinical applications as a promising framework for addressing the complex challenges posed by muscle-wasting disorders. As the field progresses, these insights offer hope for improving the quality of life and survival of affected patients.

Abstract Image

Abstract Image

Abstract Image

肌肉减少症和恶病质的最新进展:来自第17届肌肉减少症、恶病质和消耗疾病会议的见解。
第17届肌肉减少症、恶病质和消瘦疾病会议于2024年12月6日至8日在华盛顿特区举行,展示了在理解和管理肌肉消瘦疾病方面的突破性进展。根据在会议上发言的国际知名专家的演讲笔记和报告,本综述突出了会议期间讨论的关键见解和最新发展。本文综述了与慢性疾病相关的肌肉减少症、癌症恶病质和其他消耗疾病。主要发现包括确定巨噬和YouTH Optimizer途径在肌肉调节中的作用,外胞质异常A2受体-核因子-κ b诱导激酶信号在肌肉萎缩中的作用,以及线粒体功能障碍对全身健康的影响。诊断工具的进步,包括人工智能成像和新型生物标志物,正在改变这些疾病的检测和管理。新兴的治疗策略,如胰高血糖素样肽2为基础的治疗,选择性雄激素受体调节剂和细胞因子抑制剂,正在重塑治疗景观。会议强调了精准医学的重要性,将分子见解与个性化护理方法相结合,并强调了多学科康复以优化患者预后。会议还强调了有希望的临床进展,包括HIPGEN试验胎盘扩展基质细胞用于髋部骨折患者的肌肉再生,以及ponsegromab研究靶向生长/分化因子-15抑制以减轻癌症恶病质相关的肌肉萎缩。这篇综述强调了基础科学、创新诊断和临床应用的整合,作为解决肌肉萎缩疾病带来的复杂挑战的一个有希望的框架。随着该领域的发展,这些见解为改善受影响患者的生活质量和生存提供了希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Bone Metabolism
Journal of Bone Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
3.70
自引率
0.00%
发文量
23
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信